Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.
Emma Guttman-Yassky, MD, PhD
Advertisement
Emma Guttman-Yassky, MD, PhD, is the health system chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, as well as the Waldman Professor of Dermatology and Immunology.
Articles by Emma Guttman-Yassky, MD, PhD
Emma Guttman-Yassky, MD, PhD, discusses the long-term efficacy of deuruxolitinib in alopecia areata.
Emma Guttman, MD, PhD, discusses the promising potential of rocatinlimab in targeting the OX40-OX40 ligand pathway for atopic dermatitis treatment.
Emma Guttman-Yassky, MD, PhD, discusses promising hair regrowth results for alopecia areata treatments, emphasizing safety and rapid efficacy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
3
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
4
Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD
5